CJC-1295 vs Ipamorelin

Name: CJC-1295 vs Ipamorelin
Published: 2026-10-23

Updated Oct 23, 20267 sources

Key differences

1Different receptors: GHRH for CJC-1295, ghrelin for ipamorelin. They are paired, not swapped.
2Different receptors. CJC-1295 is a GHRH analog that amplifies the pulse; ipamorelin is a ghrelin-receptor agonist that triggers it. People use them together, not instead of each other.

Facts from each record, in the same words as their own pages.

CJC-1295 and Ipamorelin side by side
	CJC-1295	Ipamorelin
Category	GH axis	GH axis
Evidence	Limited human data	Limited human data
FDA status	Not FDA approvedRegulatory	Not FDA approvedRegulatory
WADA	Prohibited	Prohibited
Half-life	With DAC: 5.8 to 8.1 days in healthy adults. Without DAC: about 30 minutes per guides, never measured in humans.Competitor guide	About 2 hours after IV infusion in healthy men. Subcutaneous half-life has not been published.Clinical study
Routes	Subcutaneous injection	Subcutaneous injection
Reported doses	0.4 to 2 mg (subcutaneous injection) 100 to 400 mcg (subcutaneous injection)	100 to 400 mcg (subcutaneous injection)
Most cited frequency	1 to 2 mg a week, split into 1 or 2 injections	Once daily, before bed
Vial sizes	2 mg, 5 mgCompetitor guide	2 mg, 5 mg, 10 mgCompetitor guide
Mixed vial keeps	Fridge, 2 to 8 °C, and avoid freeze-thaw.Competitor guide	Fridge, 2 to 8 °C.Competitor guide
Protocols on file	9	10

Doses shown are what sources report, labelled by origin. Not medical advice.

7 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.